CAR T-Cell Therapy Market is Rising Rapidly at CAGR 29.8% by 2032

The global CAR T-cell therapy market size is expected to be worth around USD 88.52 billion by 2032 and growing at a CAGR of 29.8% from 2023 to 2032. The market size of CAR T-cell therapy was valued at USD 8.44 billion in 2023. The U.S. CAR T-cell therapy market size was valued at USD 1.75 billion in 2023.

What is CAR T-cell therapy?

CAR T-cell therapy is an innovative form of immunotherapy used in the treatment of cancer. This ground-breaking approach involves modifying a patient’s own T cells (a type of immune cell) to express a Chimeric Antigen Receptor (CAR) on their surface. The CAR is designed to recognize specific proteins on cancer cells.

The process begins by extracting T cells from the patient’s blood. These T cells are then genetically engineered in a laboratory to produce CARs. Once the modification is complete, the CAR T cells are multiplied in number and infused back into the patient. The introduced CAR T cells can then recognize and target cancer cells, effectively enhancing the immune system’s ability to combat the disease.

CAR T-cell therapy has shown remarkable success, particularly in treating certain types of hematologic malignancies, such as specific forms of leukemia and lymphoma. It represents a promising and transformative approach for patients who have not responded positively to conventional cancer treatments.

• According to the Leukemia Research Foundation, an estimate of6,660 new cases of acute lymphoblastic leukemia were diagnosed in 2022. This rise in cases of leukemia has propelled the demand for CAR T-cell therapy, which drives the market growth.

Full Report is Ready | Ask here for Sample Copy@ https://www.visionresearchreports.com/report/sample/40008

Key Takeaways

• North America CAR T-cell therapy market size was valued at USD 3.36 billion in 2023 and it is expected to hit around USD 35.50 billion by 2032 with a CAGR of 29.9% from 2023 to 2032.

• Europe CAR T-cell therapy market size was exhibited at USD 2.37 billion in 2023 and it is expanding around USD 25.82 billion by 2032 with a CAGR of 30.3% from 2023 to 2032.

• APAC CAR T-cell therapy market size was surpassed at USD 1.69 billion in 2023 and it is projected to reach around USD 18.65 billion by 2032, expanding at a CAGR of 30.5% from 2023 to 2032.

• LAMEA CAR T-cell therapy market size was valued at USD 1.01 billion in 2023 and it is predicted to reach around USD 8.54 billion by 2032 with a CAGR of 26.8% from 2023 to 2032.

Immediate Delivery is Available | Get Full Report Access@ https://www.visionresearchreports.com/report/checkout/40008

Therapy Price and Manufacturing Challenges Likely to Slow Down the CAR T Therapy Market Growth

Manufacturing biologics and cell therapies is considerably complex, as compared to small molecule drugs. The high manufacturing cost also contributes to high price of the therapy, essentially leading to limited adoption in case of unavailability of reimbursement. In 2021, BMS faced manufacturing bottleneck for its CAR-T idecabtagene vicleucel (ABECMA®), driven by shortage of viral vectors in addition to other reasons. In 2022, Janseen and Legend Biotech rolled out their CAR-T ciltacabtagene autoleucel (CARVYKTI ®) in a phased manner in the US instead of a nationwide launch owing to manufacturing limitations.

CAR-T Cell Market Pre-Covid

Prior to COVID-19, the industry for CAR-T cell treatment was expanding quickly and receiving considerable investment from pharmaceutical firms. For juvenile acute lymphoblastic leukemia, the FDA approved the first CAR-T cell therapy in 2017, and since then, numerous other CAR-T cell therapies have been approved for various disease types. Novartis and Gilead Sciences had the majority of the market share for CAR-T cell therapy, dominating the market. Several businesses, such as Kite Pharma, Juno Therapeutics, and Bluebird Bio, were working on CAR-T cell therapy, though.

CAR-T cell treatment is expensive, but it has been remarkably effective in curing some forms of cancer. However, there were drawbacks to the therapy, such as possible side effects, manufacturing difficulties, and expensive prices. Yet, it was anticipated that the market for CAR-T cell therapy would expand as more treatments for various cancers were discovered and given the go-ahead.

CAR-T Cell Market Post-Covid

In the post-COVID era, it is anticipated that the CAR-T cell treatment market would maintain its upward trend. The pandemic has underlined the significance of cutting-edge treatments like CAR-T cell therapy, which can provide cancer patients efficient treatment alternatives. The pandemic’s effects on clinical trials and supply chains are expected to restrict the market’s growth a little bit from earlier predictions.

The market for CAR-T cell therapy is anticipated to gain from developments in cell engineering and gene editing techniques. Better patient outcomes are anticipated as a result of these developments in CAR-T cell therapy’s accuracy and efficacy. The industry is also anticipated to gain from the rising incidence of cancer globally, especially in developing markets. However, the high cost of CAR-T cell therapy continues to be a problem, and businesses will need to make further investments in streamlining the production process to save prices.

Overall, it is anticipated that the CAR-T cell therapy market would expand in the post-COVID era, propelled by technological developments, rising cancer incidence rates, and a stronger focus on industry collaboration and innovation.

CAR T-cell Therapy Market Growth Factors

1. Clinical Success and Efficacy: Positive clinical outcomes and success stories in treating certain types of cancer, particularly hematologic malignancies like leukemia and lymphoma, have significantly boosted the demand for CAR T-cell therapy.
2. Increasing Incidence of Cancer: The rising prevalence of cancer worldwide, along with the growing awareness and adoption of advanced treatment options, has contributed to the expansion of the CAR T-cell therapy market.
3. Advancements in Genetic Engineering: Continuous advancements in genetic engineering technologies have improved the efficiency and safety of modifying T cells to express Chimeric Antigen Receptors (CARs), enhancing the overall appeal and feasibility of CAR T-cell therapy.
4. Investments and Funding: Substantial investments and funding from both public and private sectors have fueled research and development activities in the field of CAR T-cell therapy, accelerating technological advancements and market growth.
5. Regulatory Approvals: Regulatory approvals for CAR T-cell therapies by health authorities have played a crucial role in establishing these treatments as credible and effective options, fostering market growth.
6. Collaborations and Partnerships: Collaborations between pharmaceutical companies, research institutions, and healthcare organizations have facilitated the pooling of resources and expertise, fostering innovation and the development of new CAR T-cell therapies.
7. Expanding Applications: Ongoing research is expanding the applications of CAR T-cell therapy beyond hematologic malignancies, exploring its potential in treating solid tumors and other types of cancers, which is broadening the therapy’s market scope.
8. Patient Access and Adoption: As more healthcare providers offer CAR T-cell therapy and patient awareness increases, there is a growing trend of wider adoption, contributing to market growth.
9. Technological Advancements: Continuous improvements in manufacturing processes, storage, and transportation of CAR T-cell products have increased their accessibility and scalability, positively influencing market expansion.
10. Market Competition: Increasing competition among pharmaceutical companies and biotechnology firms in developing novel CAR T-cell therapies has resulted in a dynamic market environment, fostering innovation and driving overall market growth.

What are the importance of CAR T-cell therapy?

1. Precision and Specificity: CAR T-cell therapy offers a highly targeted approach to cancer treatment. By modifying a patient’s own T cells to express Chimeric Antigen Receptors (CARs), the therapy can precisely recognize and attack cancer cells while sparing healthy cells, minimizing side effects.
2. Personalized Treatment: The therapy is tailored to each patient, as it involves using their own immune cells. This personalized approach increases the likelihood of treatment success and reduces the risk of immune rejection.
3. Effective Treatment for Hematologic Malignancies: CAR T-cell therapy has demonstrated remarkable success in treating certain types of hematologic malignancies, such as leukemia and lymphoma. It has proven effective, especially in cases where traditional treatments have failed.
4. Alternative for Non-Responsive Cases: For patients who do not respond to conventional treatments like chemotherapy or radiation, CAR T-cell therapy provides a valuable alternative. It offers hope and a viable solution for individuals with limited treatment options.
5. Potential for Long-lasting Responses: In some cases, CAR T-cell therapy has shown the potential for long-lasting responses. Modified T cells can persist in the body, providing ongoing protection against cancer recurrence.
6. Reduction in Relapse Rates: CAR T-cell therapy has demonstrated lower relapse rates in certain cancer types compared to traditional treatments. This characteristic contributes to its potential for providing a more durable and sustained response.
7. Immunotherapy Approach: CAR T-cell therapy harnesses the power of the patient’s own immune system to fight cancer. This immunotherapy approach activates and enhances the body’s natural defenses, potentially leading to fewer side effects compared to traditional treatments.
8. Hope for Advanced and Refractory Cases: CAR T-cell therapy offers hope for patients with advanced or refractory cancers, where other treatment options may have limited effectiveness. It opens up new possibilities for improving outcomes in challenging cases.
9. Potential for Broad Applications: Ongoing research is exploring the application of CAR T-cell therapy beyond hematologic malignancies, including its use in treating solid tumors. This potential expansion broadens the therapy’s impact across a wider range of cancers.

Drug Type Insight

On the basis of drug type, the CAR T-cell therapy market is categorized into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and others. The axicabtagene ciloleucel segment dominated the global market in 2022 owing to high adoption of axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

Indication Insight

On the basis of indication, the market is categorized into lymphoma, acute lymphocytic leukemia, and others. The lymphoma segment dominated the global market in 2022 owing to high prevalence of lymphoma globally. This is owing to the increasing geriatric population, which is more vulnerable to such disorders.

The acute lymphocytic leukemia segment is expected to grow at a fastest CAGR during the forecast period owing to increasing occurrence of initiatives commenced by public and private organizations.

By End User Insight

On the basis of end user, the market is categorized into hospitals and cancer treatment centers. The hospitals segment dominated the market in 2022, owing to high patient base getting cancer treatment in hospitals. However, the cancer treatment centers segment is expected to register the fastest growth during the forecast period, owing to availability of a wide range of choice of treatment and increase in the number of cancer centers in some developing nations.

This is attributable to the increasing number of patients visit to the hospitals for the diagnosis of the treatment. The cancer treatment centers segment is expected to grow at a 28.9% of CAGR during the forecast period owing to the growing trend towards personalized treatments.

Regional Insight

North America dominated the market share 39.80% in terms of revenue in 2023. The growth in this region is mainly attributed to high R&D activities to develop new CAR T-cell therapies, and strong presence of key players in the region. In addition, the presence of several major players, such as Bristol-Myers Squibb, Johnson & Johnson, Gilead Sciences, and Intellia Therapeutics., and Pfizer Inc. contribute to the market growth in the region.

Europe is expected to grow at the highest rate during the forecast period. This is attributed to high prevalence rate of cancer, a large and diverse population, improving healthcare infrastructure, and rise in geriatric population as they are more prone to the cancer disease. In addition, the rise in research and clinical trials, growing awareness, and surge in pharmaceutical and biotechnology investments for the development of novel drugs are the factors that drive the market growth in this region.

Recent Developments in CAR T Therapy Market

Several recent developments have taken place in the field of CAR T cell therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In August 2023, the US FDA granted orphan drug designation (ODD) to NXC-201 (Nexcella), a next generation chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients suffering from multiple myeloma.
• In August 2023, Invectys announced that FDA granted a Fast Track Designation to the chimeric antigen receptor (CAR) T-cell therapy, IVS-3001, which is used for the treatment of patients suffering from renal cell carcinoma.
• In August 2023, GenScript Biotech entered into a strategic agreement with T-MAXIMUM Biotech with an aim to develop CAR T cell therapy by using GenScript’s CRISPR nucleic acid reagents

Check below how this report will helps you

The market research report features an extensive study of the current market size and the future potential of CAR-T therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry.

Amongst other elements, the report features the following:

• A detailed assessment of the current market landscape of CAR-T therapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
• An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
• A detailed analysis of completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
• An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
• Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
• An analysis of various type of partnership that have been inked between several stakeholders in the domain of CAR-T cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
• An analysis of the investments that have been made into CAR-T companies that have proprietary CAR-T therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
• An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
• A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
• An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR T therapy that is likely to be marketed in the coming years.
• A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
• Elaborate profiles of the several leading players in the domain of CAR T cell therapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Market Segmentation

By Drug Type

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

By End User

• Hospitals
• Cancer Treatment Centers

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By Regions

• North America
• Europe
• Asia Pacific
• LAMEA

Immediate Delivery is Available | Get Full Report Access@ https://www.visionresearchreports.com/report/checkout/40008